Limits...
Long-term results of oxybutynin use in treating facial hyperhidrosis.

Wolosker N, Teivelis MP, Krutman M, Campbell TP, Kauffman P, Campos JR, Puech-Leão P - An Bras Dermatol (2014 Nov-Dec)

Bottom Line: After six weeks, 100% of patients improved QOL.Comparing results after six weeks and on the last visit, 91.8% of patients maintained the same category of improvement in facial hyperhidrosis, 3.3% worsened and 4.9% improved.Patients who had a good initial response to treatment maintained a good response long-term, did not display tachiphylaxis and experienced improvement on other hyperhidrosis sites.

View Article: PubMed Central - PubMed

Affiliation: Hospital Israelita Albert Einstein, São Paulo, SP, Brazil.

ABSTRACT

Background: Facial hyperhidrosis can lead to serious emotional distress. Video-assisted thoracic sympathectomy resolves symptoms effectively, though it may be associated with compensatory hyperhidrosis, which may be more common in patients undergoing resection of the second thoracic ganglion. Oxybutynin has been used as a pharmacological approach to facial hyperhidrosis but the long-term results of this treatment are unclear.

Objective: To evaluate the use of low oxybutynin doses in facial hyperhidrosis patients for at least six months.

Methods: 61 patients were monitored for over six months and assessed according to the following variables: impact of hyperhidrosis on quality of life (QOL) before treatment and after six weeks, evolution of facial hyperhidrosis after six weeks and at the last consultation, complaints of dry mouth after six weeks and on last return visit, and improvement at other hyperhidrosis sites.

Results: Patients were monitored for 6 to 61 months (median=17 months). Thirty-six (59%) were female. Age ranged from 17-74 (median:45). Pre-treatment QOL was poor/very poor in 96.72%. After six weeks, 100% of patients improved QOL. Comparing results after six weeks and on the last visit, 91.8% of patients maintained the same category of improvement in facial hyperhidrosis, 3.3% worsened and 4.9% improved. Dry mouth complaints were common but not consistent throughout treatment. More than 90% of patients presented moderate/great improvement at other hyperhidrosis sites.

Conclusion: Patients who had a good initial response to treatment maintained a good response long-term, did not display tachiphylaxis and experienced improvement on other hyperhidrosis sites.

Show MeSH

Related in: MedlinePlus

Follow-up algorithm of pharmacologically treated patients with facialhyperhidrosis
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4230660&req=5

f01: Follow-up algorithm of pharmacologically treated patients with facialhyperhidrosis

Mentions: From September 2007 to September 2013, a total of 98 consecutive patients, whose maincomplaint was facial hyperhidrosis, were enrolled at our institutions. Seven patientsfailed to attend their first return visits. Of the remaining 91, twelve (13.2%) patientsdid not improve after six weeks and left the study due to their nonimprovement followingpharmacological treatment. A further two additional patients reported severe dry mouthand left the study. Seventy-seven patients were treated with oxybutynin for six weeks.Sixteen were monitored for under six months, while 61 were monitored for over sixmonths. The latter were the patients analyzed. Figure1 graphically represents the series.


Long-term results of oxybutynin use in treating facial hyperhidrosis.

Wolosker N, Teivelis MP, Krutman M, Campbell TP, Kauffman P, Campos JR, Puech-Leão P - An Bras Dermatol (2014 Nov-Dec)

Follow-up algorithm of pharmacologically treated patients with facialhyperhidrosis
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4230660&req=5

f01: Follow-up algorithm of pharmacologically treated patients with facialhyperhidrosis
Mentions: From September 2007 to September 2013, a total of 98 consecutive patients, whose maincomplaint was facial hyperhidrosis, were enrolled at our institutions. Seven patientsfailed to attend their first return visits. Of the remaining 91, twelve (13.2%) patientsdid not improve after six weeks and left the study due to their nonimprovement followingpharmacological treatment. A further two additional patients reported severe dry mouthand left the study. Seventy-seven patients were treated with oxybutynin for six weeks.Sixteen were monitored for under six months, while 61 were monitored for over sixmonths. The latter were the patients analyzed. Figure1 graphically represents the series.

Bottom Line: After six weeks, 100% of patients improved QOL.Comparing results after six weeks and on the last visit, 91.8% of patients maintained the same category of improvement in facial hyperhidrosis, 3.3% worsened and 4.9% improved.Patients who had a good initial response to treatment maintained a good response long-term, did not display tachiphylaxis and experienced improvement on other hyperhidrosis sites.

View Article: PubMed Central - PubMed

Affiliation: Hospital Israelita Albert Einstein, São Paulo, SP, Brazil.

ABSTRACT

Background: Facial hyperhidrosis can lead to serious emotional distress. Video-assisted thoracic sympathectomy resolves symptoms effectively, though it may be associated with compensatory hyperhidrosis, which may be more common in patients undergoing resection of the second thoracic ganglion. Oxybutynin has been used as a pharmacological approach to facial hyperhidrosis but the long-term results of this treatment are unclear.

Objective: To evaluate the use of low oxybutynin doses in facial hyperhidrosis patients for at least six months.

Methods: 61 patients were monitored for over six months and assessed according to the following variables: impact of hyperhidrosis on quality of life (QOL) before treatment and after six weeks, evolution of facial hyperhidrosis after six weeks and at the last consultation, complaints of dry mouth after six weeks and on last return visit, and improvement at other hyperhidrosis sites.

Results: Patients were monitored for 6 to 61 months (median=17 months). Thirty-six (59%) were female. Age ranged from 17-74 (median:45). Pre-treatment QOL was poor/very poor in 96.72%. After six weeks, 100% of patients improved QOL. Comparing results after six weeks and on the last visit, 91.8% of patients maintained the same category of improvement in facial hyperhidrosis, 3.3% worsened and 4.9% improved. Dry mouth complaints were common but not consistent throughout treatment. More than 90% of patients presented moderate/great improvement at other hyperhidrosis sites.

Conclusion: Patients who had a good initial response to treatment maintained a good response long-term, did not display tachiphylaxis and experienced improvement on other hyperhidrosis sites.

Show MeSH
Related in: MedlinePlus